EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cell Reprogramming: Therapeutic Advances and Challenges

Aiqing Li, Zhipeng Wang, Zhaojie Lyu, Zhouting Tuo, Xinrui Li, Rui-Cheng Wu, Jie Wang, Dilinaer Wusiman, Yifan Wang, Qi Zhang, Wei Xiong, Bo Zhou und 1 weitere

Research · 01.01.2026 · 9

DOI: 10.34133/research.1472 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Research, online erschienen am 10.11.2026. Verfasst von Aiqing Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Center of Psychosomatic Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichua…. Die Arbeit nennt 190 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health Commission of the People’s Republic of China-Zhejiang Province Jointly Constructed Project, Zhejiang Province Medical and Health Science and Te…, Clinical-Basic Joint Research Project of Zhejiang Provincial People’s Hospital Affiliated with Hangzhou Medical College.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell reprogramming, which forcibly alters cell fate, offers a novel therapeutic strategy for various refractory diseases. Unlike previous reviews focused on a single disease context or a single reprogramming modality, this review is organized around therapeutic applications. It summarizes advances in direct reprogramming, partial reprogramming, and cell fusion-induced reprogramming and further compares their mechanisms, challenges in clinical translation, and safety boundaries. In oncology, reprogramming cancer cells into antigen-presenting cells elicits durable antitumor immunity and remodels the tumor microenvironment, whereas converting cancer cells into nonmalignant somatic cells can reduce their malignant phenotype and tumorigenic potential. In neurodegenerative diseases, direct reprogramming has converted fibroblasts or astrocytes into functional dopaminergic and cortical neurons both in vitro and in vivo. In mouse models of progeria and natural aging, partial reprogramming strategies markedly extend lifespan, ameliorate multiorgan pathology, and enhance tissue regenerative capacity. However, the strength and reproducibility of these findings vary across experimental models, and reported therapeutic benefits do not necessarily establish complete, stable, or safe cell-fate conversion. Against this predominantly preclinical background, ER-100 is the first regenerative therapy based on partial epigenetic reprogramming to receive Food and Drug Administration Investigational New Drug approval and enter clinical testing. It therefore provides an important reference point for the transition from animal studies to human trials. Cell fusion-induced reprogramming has context-dependent roles in tumor immunity. Fusion between tumor cells and immune cells may promote malignant progression. In contrast, dendritic cell–tumor cell fusion vaccines and chimeric exosomes can activate antitumor immune responses in preclinical models and early clinical studies. Major barriers to clinical translation include low reprogramming efficiency, an incompletely defined safety window, and the need to select in vivo or ex vivo strategies according to disease context. In addition, insufficient delivery efficiency, poor targeting, and long-term tumorigenic risk remain important constraints on clinical application. Looking ahead, single-cell multiomics and artificial intelligence may help optimize reprogramming factor combinations, while nonviral systems may improve targeted delivery. Integration with tissue engineering may further facilitate clinical translation across oncology, aging, regenerative medicine, autoimmune diseases, and neuropsychiatric disorders.

Autor:innen und Institutionen

  • The Center of Psychosomatic Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • Department of Urology, Institute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
  • Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Division of Surgery & Interventional Science, University College London, London, UK.

ORCID-Profile: Dechao Feng

Förderung

  • National Health Commission of the People’s Republic of China-Zhejiang Province Jointly Constructed Project, Zhejiang Province Medical and Health Science and Te…
  • Clinical-Basic Joint Research Project of Zhejiang Provincial People’s Hospital Affiliated with Hangzhou Medical College

Zitieren

APA

Li, A., Wang, Z., Lyu, Z., Tuo, Z., Li, X., Wu, R. C., Wang, J., Wusiman, D., Wang, Y., Zhang, Q., Xiong, W., Zhou, B., & Feng, D. (2026). Cell Reprogramming: Therapeutic Advances and Challenges. Research, 9. https://doi.org/10.34133/research.1472

Vancouver

Li A, Wang Z, Lyu Z, Tuo Z, Li X, Wu RC, et al. Cell Reprogramming: Therapeutic Advances and Challenges. Research. 2026;9. doi:10.34133/research.1472

BibTeX
@article{Li2026,
  author = {Li, Aiqing and Wang, Zhipeng and Lyu, Zhaojie and Tuo, Zhouting and Li, Xinrui and Wu, Rui-Cheng and Wang, Jie and Wusiman, Dilinaer and Wang, Yifan and Zhang, Qi and Xiong, Wei and Zhou, Bo and Feng, Dechao},
  title = {Cell Reprogramming: Therapeutic Advances and Challenges},
  journal = {Research},
  year = {2026},
  volume = {9},
  doi = {10.34133/research.1472}
}
Kostenlos starten →